CJC-1295 + Ipamorelin
$50.00MG
In stock
Overview
This blend represents one of the most synergistic combinations in growth hormone research. Think of it as a perfectly choreographed duet where CJC-1295 without DAC (also known as Mod GRF 1-29) acts as the conductor, extending the duration of each growth hormone performance, while Ipamorelin serves as the virtuoso soloist, creating powerful crescendos of hormone release. Neither peptide overwhelms the body’s natural rhythms; instead, they enhance and optimize what nature intended.
What makes this combination particularly elegant is how each peptide addresses different aspects of growth hormone secretion. CJC-1295 without DAC works by preventing the breakdown of your body’s own growth hormone-releasing hormone, effectively keeping the signal to produce GH active for longer periods. Meanwhile, Ipamorelin selectively triggers the pituitary to release stronger pulses of growth hormone without affecting other hormones like cortisol or prolactin. The result? A more physiological pattern of GH release that researchers find produces 3-5 times more growth hormone than either peptide alone.
Blend Composition
PEPTIDE COMPONENTS
- CJC-1295 no DAC: 5mg (Modified GRF 1-29)
- Ipamorelin: 5mg (Pentapeptide)
- Total Peptide: 10mg
- Ratio: 1:1 Equal blend
PHYSICAL PROPERTIES
- Form: White lyophilized powder
- Solubility: Readily dissolves in water
- Stability: Enhanced compared to native GHRH
- Storage: Keep refrigerated 36‑46 °F (2‑8 °C)
Synergistic Mechanisms
CJC-1295 without DAC Actions
GHRH Analog Function
Modified version of GHRH (1-29) with enhanced stability
Extended Half-Life
30-minute half-life vs 7 minutes for native GHRH
Pulse Frequency
Increases the frequency of GH pulses
Resistance to Degradation
Four amino acid substitutions prevent enzymatic breakdown
Ipamorelin Actions
Ghrelin Receptor Agonist
Selective activation of GHS-R1a receptors
Pulse Amplitude
Increases the strength of each GH pulse
Selective Action
No effect on cortisol, prolactin, or ACTH
Rapid Onset
Fast-acting with 2-hour half-life
Combined Synergistic Effects
3-5x GH Increase:
Significantly higher than either peptide alone
Natural Pulsatility:
Maintains physiological GH release patterns
Extended Duration:
Longer-lasting effects with rapid onset
Selective Action:
GH-specific without affecting other hormones
Research Applications
Metabolic Function Studies
- Enhanced fat metabolism and lipolysis
- Improved insulin sensitivity markers
- Better glucose utilization
- Increased metabolic rate
- Optimized nutrient partitioning
Body Composition Research
- Increased lean muscle mass development
- Reduced body fat percentage
- Enhanced muscle protein synthesis
- Improved muscle-to-fat ratio
- Better overall body recomposition
Recovery and Regeneration
- Accelerated post-exercise recovery
- Improved connective tissue repair
- Enhanced bone mineral density
- Faster wound healing
- Reduced recovery time between training
Sleep and Well-being
- Improved deep sleep quality
- Enhanced REM sleep patterns
- Better mood and cognitive function
- Increased energy levels
- Improved stress resilience
Age-Related Research
- Improved skin elasticity and thickness
- Enhanced collagen production
- Better cellular regeneration
- Reduced age-related muscle loss
- Improved mitochondrial function
Cardiovascular Health
- Improved cardiac output
- Better endothelial function
- Enhanced lipid profiles
- Reduced inflammatory markers
- Improved vascular flexibility
Research Advantages
Superior Efficacy
3-5 fold increase in GH release compared to single peptides
Selective Action
GH-specific without affecting cortisol or prolactin
Physiological Pattern
Maintains natural pulsatile GH secretion
Complementary Kinetics
Fast onset from Ipamorelin, extended duration from CJC-1295
No Desensitization
Sustained effectiveness with continued research use
Research Flexibility
1:1 ratio allows easy dosing calculations
References
- Ishida J, et al. “Growth hormone secretagogues: history, mechanism of action, and clinical development.” JCSM Rapid Communications. 2020.
- Deepankar K, et al. “Beyond the androgen receptor: the role of growth hormone secretagogues in body composition.” Transl Androl Urol. 2020.
- Walpurgis K, et al. “An immuno-PCR screen for detection of CJC-1295 and GH-releasing hormone analogs.” Drug Test Anal. 2019.
- Sackmann-Sala L, et al. “Activation of the GH/IGF-1 axis by CJC-1295.” Growth Horm IGF Res. 2009.
- Veldhuis JD, et al. “Synergistic release of growth hormone by GHRH and GHRP.” Pituitary. 2009.
- Ionescu M, Frohman LA. “Pulsatile secretion of growth hormone persists during continuous stimulation.” J Clin Endocrinol Metab. 2006.
- Teichman SL, et al. “Prolonged stimulation of GH and IGF-I secretion by CJC-1295.” J Clin Endocrinol Metab. 2006.
- Alba M, et al. “Once-daily administration of CJC-1295.” J Clin Endocrinol Metab. 2005.
- Beck DE, et al. “Comparison of ipamorelin and GHRP-6 effects.” Peptides. 2002.
- Jimenez-Reina L, et al. “Influence of ipamorelin on the GH/IGF-1 axis.” Growth Horm IGF Res. 2001.
- Gobburu JV, et al. “Pharmacokinetics/dynamics of ipamorelin.” J Clin Pharmacol. 1999.
- Raun K, et al. “Ipamorelin, the first selective growth hormone secretagogue.” Eur J Endocrinol. 1998.
Related products
